176 related articles for article (PubMed ID: 34837383)
1. Oxidized phospholipids and lipoprotein(a): An update.
Koutsogianni AD; Liberopoulos E; Tellis K; Tselepis AD
Eur J Clin Invest; 2022 Apr; 52(4):e13710. PubMed ID: 34837383
[TBL] [Abstract][Full Text] [Related]
2. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
Tsimikas S; Tsironis LD; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2094-9. PubMed ID: 17626905
[TBL] [Abstract][Full Text] [Related]
3. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).
Tsimikas S; Duff GW; Berger PB; Rogus J; Huttner K; Clopton P; Brilakis E; Kornman KS; Witztum JL
J Am Coll Cardiol; 2014 May; 63(17):1724-34. PubMed ID: 24530664
[TBL] [Abstract][Full Text] [Related]
4. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.
Bergmark C; Dewan A; Orsoni A; Merki E; Miller ER; Shin MJ; Binder CJ; Hörkkö S; Krauss RM; Chapman MJ; Witztum JL; Tsimikas S
J Lipid Res; 2008 Oct; 49(10):2230-9. PubMed ID: 18594118
[TBL] [Abstract][Full Text] [Related]
5. Oxidized phospholipids in cardiovascular disease.
Tsimikas S; Witztum JL
Nat Rev Cardiol; 2024 Mar; 21(3):170-191. PubMed ID: 37848630
[TBL] [Abstract][Full Text] [Related]
6. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity.
Tsimikas S; Witztum JL
Curr Opin Lipidol; 2008 Aug; 19(4):369-77. PubMed ID: 18607184
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
8. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.
Boffa MB; Koschinsky ML
Nat Rev Cardiol; 2019 May; 16(5):305-318. PubMed ID: 30675027
[TBL] [Abstract][Full Text] [Related]
9. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).
Leibundgut G; Scipione C; Yin H; Schneider M; Boffa MB; Green S; Yang X; Dennis E; Witztum JL; Koschinsky ML; Tsimikas S
J Lipid Res; 2013 Oct; 54(10):2815-30. PubMed ID: 23828779
[TBL] [Abstract][Full Text] [Related]
10. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
[TBL] [Abstract][Full Text] [Related]
11. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.
van der Valk FM; Bekkering S; Kroon J; Yeang C; Van den Bossche J; van Buul JD; Ravandi A; Nederveen AJ; Verberne HJ; Scipione C; Nieuwdorp M; Joosten LA; Netea MG; Koschinsky ML; Witztum JL; Tsimikas S; Riksen NP; Stroes ES
Circulation; 2016 Aug; 134(8):611-24. PubMed ID: 27496857
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids.
Sharma M; Von Zychlinski-Kleffmann A; Porteous CM; Jones GT; Williams MJ; McCormick SP
J Lipid Res; 2015 Jul; 56(7):1318-28. PubMed ID: 25852127
[TBL] [Abstract][Full Text] [Related]
13. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.
Faghihnia N; Tsimikas S; Miller ER; Witztum JL; Krauss RM
J Lipid Res; 2010 Nov; 51(11):3324-30. PubMed ID: 20713651
[TBL] [Abstract][Full Text] [Related]
14. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma.
Wiesner P; Tafelmeier M; Chittka D; Choi SH; Zhang L; Byun YS; Almazan F; Yang X; Iqbal N; Chowdhury P; Maisel A; Witztum JL; Handel TM; Tsimikas S; Miller YI
J Lipid Res; 2013 Jul; 54(7):1877-83. PubMed ID: 23667177
[TBL] [Abstract][Full Text] [Related]
15. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
[TBL] [Abstract][Full Text] [Related]
16. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins.
Schneider M; Witztum JL; Young SG; Ludwig EH; Miller ER; Tsimikas S; Curtiss LK; Marcovina SM; Taylor JM; Lawn RM; Innerarity TL; Pitas RE
J Lipid Res; 2005 Apr; 46(4):769-78. PubMed ID: 15654123
[TBL] [Abstract][Full Text] [Related]
17. Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.
Tsimikas S
Circ Res; 2019 Feb; 124(3):405-415. PubMed ID: 30702993
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a): Expanding our knowledge of aortic valve narrowing.
Youssef A; Clark JR; Koschinsky ML; Boffa MB
Trends Cardiovasc Med; 2021 Jul; 31(5):305-311. PubMed ID: 32525013
[TBL] [Abstract][Full Text] [Related]
19. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.
Taleb A; Witztum JL; Tsimikas S
Biomark Med; 2011 Oct; 5(5):673-94. PubMed ID: 22003918
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum.
Koschinsky ML; Boffa MB
Endocrinol Metab Clin North Am; 2014 Dec; 43(4):949-62. PubMed ID: 25432390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
